GANX - Gain Therapeutics Inc logo

Gain Therapeutics Inc

GANX

Gain Therapeutics, Inc. develops small molecule therapeutics targeting protein misfolding diseases. Its drug discovery platform identifies allosteric binding sites, with lead candidate GT-02287 in Phase 1b for Parkinson's disease and various preclinical candidates.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$187today

Score Overview

1 Year
Scoreโ€”
Net Growth0.27%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.3
Net Growth-44.75%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev TrendNever
Revenue Consistencyโ€”
All Time
Score
Net Growth-44.75%
Net Trend60%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Gain Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. GANX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 1.29โ€”
1 Year2025-10-22
$ 2.01-35.82%
5 Years2021-10-22
$ 6.90-81.30%
All Time2021-03-18
$ 11.20-88.48%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 20M$ 13M
2025$ 0.00-$ 20M$ 20M
2024$ 0.00-$ 20M$ 10M
2023$ 55.18K-$ 22M$ 16M
2022$ 140.11K-$ 17M$ 20M
IPO2021$ 164.99K-$ 13M$ 36M
GANX - Gain Therapeutics Inc logo

Gain Therapeutics Inc fundamental performance

Between 2021 and 2025, revenue declined from $ 164.99K to $ 0.00 and net income went from -$ 13M to -$ 20M. Revenue increased in 0% of the years measured; net income in 60%.

Gain Therapeutics Inc currently holds a 5-year HDB Score of 3.3 out of 10. How the HDB Score is calculated.

Membership

Explore GANX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies